- Home
- SCYX vs FOXX Comparison
SCYX vs FOXX Comparison
Compare SCYX & FOXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- FOXX
- Stock Information
- Founded
- SCYX 1999
- FOXX 2017
- Country
- SCYX United States
- FOXX United States
- Employees
- SCYX N/A
- FOXX N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- FOXX
- Sector
- SCYX Health Care
- FOXX
- Exchange
- SCYX Nasdaq
- FOXX Nasdaq
- Market Cap
- SCYX 32.3M
- FOXX 30.5M
- IPO Year
- SCYX 2014
- FOXX N/A
- Fundamental
- Price
- SCYX $0.60
- FOXX $3.15
- Analyst Decision
- SCYX Strong Buy
- FOXX
- Analyst Count
- SCYX 1
- FOXX 0
- Target Price
- SCYX $3.00
- FOXX N/A
- AVG Volume (30 Days)
- SCYX 570.0K
- FOXX 19.8K
- Earning Date
- SCYX 11-05-2025
- FOXX 10-24-2025
- Dividend Yield
- SCYX N/A
- FOXX N/A
- EPS Growth
- SCYX N/A
- FOXX N/A
- EPS
- SCYX N/A
- FOXX N/A
- Revenue
- SCYX $2,932,000.00
- FOXX $65,919,166.00
- Revenue This Year
- SCYX $368.39
- FOXX N/A
- Revenue Next Year
- SCYX $123.36
- FOXX N/A
- P/E Ratio
- SCYX N/A
- FOXX N/A
- Revenue Growth
- SCYX N/A
- FOXX 1941.75
- 52 Week Low
- SCYX $0.58
- FOXX $2.45
- 52 Week High
- SCYX $1.49
- FOXX $11.00
- Technical
- Relative Strength Index (RSI)
- SCYX 23.64
- FOXX 27.91
- Support Level
- SCYX $0.68
- FOXX $3.15
- Resistance Level
- SCYX $0.65
- FOXX $3.71
- Average True Range (ATR)
- SCYX 0.04
- FOXX 0.32
- MACD
- SCYX -0.01
- FOXX -0.06
- Stochastic Oscillator
- SCYX 5.83
- FOXX 24.09
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About FOXX Foxx Development Holdings Inc. Common Stock
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.